{"id":40631,"date":"2025-09-03T15:31:58","date_gmt":"2025-09-03T07:31:58","guid":{"rendered":"https:\/\/flcube.com\/?p=40631"},"modified":"2025-09-03T15:31:58","modified_gmt":"2025-09-03T07:31:58","slug":"enlaza%e2%80%91vertex-partner-on-45-m-multi%e2%80%91target-drug-discovery-collaboration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40631","title":{"rendered":"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration"},"content":{"rendered":"\n<p>Enlaza Therapeutics, Inc. and Vertex Pharmaceuticals, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/VRTX:NASDAQ\">NASDAQ: VRTX<\/a>) today announced a multi\u2011target drug discovery collaboration that will leverage Enlaza\u2019s proprietary War\u2011Lock\u2122 Technology platform to create next\u2011generation small\u2011format drug conjugates (SDCs) and T\u2011cell engagers (TCEs). The partnership targets autoimmune diseases and aims to improve conditioning regimens for sickle cell disease (SCD) and beta\u2011thalassemia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront Payment &amp; Equity<\/strong> \u2013 Enlaza will receive <strong>$45\u202fmillion<\/strong>, comprising an upfront cash payment and a strategic equity investment from Vertex.<\/li>\n\n\n\n<li><strong>Future Milestones<\/strong> \u2013 Enlaza is eligible for <strong>> $2\u202fbillion<\/strong> in milestone payments tied to research, development, regulatory, and commercial achievements.<\/li>\n\n\n\n<li><strong>Royalties<\/strong> \u2013 Tiered royalties on net sales of any product candidates that reach the market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-research-amp-development-pathway\">Research &amp; Development Pathway<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Responsibility<\/th><th>Key Actions<\/th><\/tr><\/thead><tbody><tr><td><strong>Discovery &amp; Candidate Nomination<\/strong><\/td><td>Enlaza<\/td><td>Lead all research activities, identify and nominate candidates for development.<\/td><\/tr><tr><td><strong>Preclinical &amp; Clinical Development<\/strong><\/td><td>Vertex<\/td><td>Lead all subsequent R&amp;D, manufacturing, and regulatory activities.<\/td><\/tr><tr><td><strong>Manufacturing &amp; Commercialization<\/strong><\/td><td>Vertex<\/td><td>Provide full funding for the four\u2011year collaboration and oversee production and market launch.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Vertex will finance all R&amp;D costs associated with the collaboration, ensuring a streamlined path from bench to bedside.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-focus\">Therapeutic Focus<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Autoimmune Diseases<\/strong> \u2013 Development of SDCs and TCEs aimed at conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.<\/li>\n\n\n\n<li><strong>Sickle Cell Disease &amp; Beta\u2011Thalassemia<\/strong> \u2013 Design of novel conditioning agents to enhance the safety and efficacy of curative therapies, including gene editing and stem\u2011cell transplantation.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enlaza<\/strong> gains early funding and a powerful partner with Vertex\u2019s world\u2011class manufacturing and commercialization capabilities.<\/li>\n\n\n\n<li><strong>Vertex<\/strong> expands its pipeline into autoimmune indications and augments its sickle cell and thalassemia programs with targeted, next\u2011generation modalities.<\/li>\n\n\n\n<li>The collaboration exemplifies the growing trend of technology\u2011centric partnerships that combine platform science with established drug\u2011development expertise.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Enlaza Therapeutics, Inc. and Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) today announced a multi\u2011target drug discovery&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40634,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,4330,4331,1073,24,2790,1074],"class_list":["post-40631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-enlaza-therapeutics","tag-nasdaq-enza","tag-nasdaq-vrtx","tag-rare-orphan-disease-drugs","tag-t-cell-engager","tag-vertex-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Enlaza Therapeutics and Vertex Pharmaceuticals announce a $45\u202fmillion partnership to develop small\u2011format drug conjugates and T\u2011cell engagers for autoimmune diseases, sickle cell disease, and beta\u2011thalassemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40631\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration\" \/>\n<meta property=\"og:description\" content=\"Enlaza Therapeutics and Vertex Pharmaceuticals announce a $45\u202fmillion partnership to develop small\u2011format drug conjugates and T\u2011cell engagers for autoimmune diseases, sickle cell disease, and beta\u2011thalassemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40631\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T07:31:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0309.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration\",\"datePublished\":\"2025-09-03T07:31:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631\"},\"wordCount\":311,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0309.webp\",\"keywords\":[\"Auto-immune\",\"Enlaza Therapeutics\",\"NASDAQ: ENZA\",\"NASDAQ: VRTX\",\"Rare \\\/ orphan disease drugs\",\"T cell engager\",\"Vertex Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40631#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40631\",\"name\":\"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0309.webp\",\"datePublished\":\"2025-09-03T07:31:58+00:00\",\"description\":\"Enlaza Therapeutics and Vertex Pharmaceuticals announce a $45\u202fmillion partnership to develop small\u2011format drug conjugates and T\u2011cell engagers for autoimmune diseases, sickle cell disease, and beta\u2011thalassemia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40631\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0309.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0309.webp\",\"width\":1080,\"height\":608,\"caption\":\"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40631#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration - Insight, China&#039;s Pharmaceutical Industry","description":"Enlaza Therapeutics and Vertex Pharmaceuticals announce a $45\u202fmillion partnership to develop small\u2011format drug conjugates and T\u2011cell engagers for autoimmune diseases, sickle cell disease, and beta\u2011thalassemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40631","og_locale":"en_US","og_type":"article","og_title":"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration","og_description":"Enlaza Therapeutics and Vertex Pharmaceuticals announce a $45\u202fmillion partnership to develop small\u2011format drug conjugates and T\u2011cell engagers for autoimmune diseases, sickle cell disease, and beta\u2011thalassemia.","og_url":"https:\/\/flcube.com\/?p=40631","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-03T07:31:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0309.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40631#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40631"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration","datePublished":"2025-09-03T07:31:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40631"},"wordCount":311,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40631#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0309.webp","keywords":["Auto-immune","Enlaza Therapeutics","NASDAQ: ENZA","NASDAQ: VRTX","Rare \/ orphan disease drugs","T cell engager","Vertex Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40631#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40631","url":"https:\/\/flcube.com\/?p=40631","name":"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40631#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40631#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0309.webp","datePublished":"2025-09-03T07:31:58+00:00","description":"Enlaza Therapeutics and Vertex Pharmaceuticals announce a $45\u202fmillion partnership to develop small\u2011format drug conjugates and T\u2011cell engagers for autoimmune diseases, sickle cell disease, and beta\u2011thalassemia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40631#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40631"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40631#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0309.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0309.webp","width":1080,"height":608,"caption":"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40631#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Enlaza\u2011Vertex Partner on $45\u202fM Multi\u2011Target Drug Discovery Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0309.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40631"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40631\/revisions"}],"predecessor-version":[{"id":40635,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40631\/revisions\/40635"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40634"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}